Clinical trials: Duodenal Ulcer
Gastritis, Gastric Ulcer
A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers
The Purpose of a randomized, double-blind, placebo-controlled, single-dose, dose-escalation clinical trial is to explore investigate the safety, tolerability, pharmacokinetics, and food effect of PMK-S005 after oral…
- Trial name
- NCT01762397
- Testing
- PMK-S005
- Where
- South Korea
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- PharmaKing
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease (GERD), Peptic Ulcers
Long-term Pantoprazole Trial in Patients With Symptoms of Chronic Acid Peptic Complaints (BY1023/VMG-708)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD might occur when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00261300
- Testing
- Pantoprazole
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Takeda
Gastric Ulcer
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer
To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg…
- Trial name
- NCT02761512
- Testing
- CJ-12420 50 mg QD, CJ-12420 100 mg QD, Lansoprazole 30 mg QD
- Where
- 2 sites in South Korea
- Volunteers
- 306 people
- Sponsor
- HK inno.N Corporation
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis
This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.
- Trial name
- NCT01538849
- Testing
- Esomeprazole 40mg, YH4808 A mg, YH4808 B mg
- Where
- South Korea
- Volunteers
- 154 people
- Sponsor
- Yuhan Corporation
Stomach Ulcer, Duodenal Ulcer
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
The purpose of this study is to determine whether lansoprazole, once daily (QD), compared to gefarnate, twice daily (BID), is effective in preventing the recurrence of gastric and duodenal ulcers in patients receiving long term…
- Trial name
- NCT00762359
- Testing
- Lansoprazole, Gefarnate
- Where
- 65 sites in Japan
- Volunteers
- 461 people
- Sponsor
- Takeda
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis
To evaluate the efficacy and safety of X842 Capsules 50 mg compared to Lansoprazole Enteric Capsules for the treatment of reflux esophagitis, and to characterize the population pharmacokinetics of X842 capsules in this patient…
- Trial name
- X842 (NCT07079540)
- Testing
- X842, Lansoprazole
- Where
- 53 sites in China
- Volunteers
- 380 people
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at…
- Trial name
- NCT00527787
- Testing
- PN400 (VIMOVO), Naproxen
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- POZEN
Acute Gastritis, Gastric Ulcer
Efficacy and Safety of Teprenone in Patients With Acute Gastritis, Acute Gastric Lesion of Chronic Gastritis With Acute Exacerbation or Gastric Ulcer
This is a self-controlled, open, multiple-center clinical trial.
- Trial name
- NCT01190657
- Testing
- Selbex
- Where
- 26 sites in China
- Volunteers
- 1,184 people
- Sponsor
- Eisai Co., Ltd.
Peptic Ulcer
Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding
To assess the efficacy and safety of the early administration of somatostatin in infusion during 72 hours plus 2 boluses, compared to placebo in the control of acute severe UGIB with suspicion of PUB.
- Trial name
- NCT00152399
- Testing
- Somatostatin UCB (drug)
- Where
- 22 sites in Belgium, France and 4 more
- Volunteers
- 370 people
- Sponsor
- UCB Pharma
Gastric Ulcers, Duodenal Ulcers
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.
- Trial name
- NCT01452763
- Testing
- TAK-438, Lansoprazole
- Where
- 76 sites in Japan
- Volunteers
- 621 people
- Sponsor
- Takeda
Peptic Ulcer, NSAID-Induced Peptic Ulcer
Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice
This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.
- Trial name
- NCT07558707
- Where
- South Korea
- Volunteers
- 7,000 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Peptic Ulcer
AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers
AGN 201904, a proton pump inhibitor, versus esomeprazole in the prevention of stomach or upper intestinal damage following administration of high-dose aspirin in healthy volunteers
- Trial name
- NCT00325715
- Testing
- AGN 201904, esomeprazole
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Allergan
Esophagitis, Reflux
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis.
- Trial name
- NCT00282555
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- 17 sites in Canada
- Volunteers
- 450 people
- Sponsor
- STEBA France
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Maintenance Treatment)
The primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once daily for 24 weeks on maintenance of Reflux Esophagitis in patients with healed reflux esophagitis in comparison with omeprazole 10 mg…
- Trial name
- NCT00634114
- Testing
- Esomeprazole, Omeprazole
- Where
- 44 sites in Japan
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux
Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.
- Trial name
- NCT00229424
- Testing
- Lafutidine, Famotidine
- Where
- Japan
- Volunteers
- 325 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Esophagitis, Gastroesophageal Reflux
Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers
S-Tenatoprazole-Na (STU-Na), a new drug currently under clinical development, belongs to a class of drugs, called proton pump inhibitors (PPls). Some PPIs are already commercially available.
- Conditions
- Esophagitis, Gastroesophageal Reflux, Stomach Ulcer, Duodenal Ulcer
- Trial name
- NCT00284908
- Testing
- S-Tenatoprazole-Na (STU-Na)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- STEBA France
Gastric Acid Suppression, Proton Pump Inhibitors
Survey Examining the Frequency and Severity of Acid Related Symptoms While Taking Nexium
This study will assess the effectiveness of Nexium at alleviating upper GI symptoms in subjects and evaluate with which treatment regimen and on which indications acid suppression with isomeric proton pump inhibitor is used in…
- Trial name
- NCT01130935
- Where
- 14 sites in Albania
- Volunteers
- 491 people
- Sponsor
- AstraZeneca